Compare CGBD & NBTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | CGBD | NBTX |
|---|---|---|
| Founded | 2012 | 2003 |
| Country | United States | France |
| Employees | N/A | N/A |
| Industry | Finance: Consumer Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 906.2M | 1.0B |
| IPO Year | 2017 | 2020 |
| Metric | CGBD | NBTX |
|---|---|---|
| Price | $12.61 | $22.28 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 7 | 1 |
| Target Price | ★ $13.70 | $8.00 |
| AVG Volume (30 Days) | ★ 518.4K | 42.6K |
| Earning Date | 11-04-2025 | 09-30-2025 |
| Dividend Yield | ★ 12.89% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 1.14 | N/A |
| Revenue | ★ $245,008,000.00 | $11,930,711.00 |
| Revenue This Year | $13.53 | N/A |
| Revenue Next Year | $4.24 | $136.64 |
| P/E Ratio | $11.25 | ★ N/A |
| Revenue Growth | ★ 2.55 | N/A |
| 52 Week Low | $11.55 | $2.82 |
| 52 Week High | $18.64 | $30.35 |
| Indicator | CGBD | NBTX |
|---|---|---|
| Relative Strength Index (RSI) | 47.85 | 53.86 |
| Support Level | $12.64 | $21.44 |
| Resistance Level | $12.95 | $22.96 |
| Average True Range (ATR) | 0.21 | 0.75 |
| MACD | -0.03 | 0.00 |
| Stochastic Oscillator | 9.46 | 55.59 |
Carlyle Secured Lending Inc is a specialty finance company that is a closed-end, externally managed, non-diversified management investment company. It focuses on providing directly originated, financing solutions across the capital structure, with a focus on senior secured lending to middle-market companies located in the United States. The company's investment objective is to generate current income and capital appreciation through debt investments in U.S. middle-market companies.
Nanobiotix SA is a clinical-stage biotechnology company that has one operating segment, which focuses on developing product candidates that use its proprietary nanotechnology to transform cancer treatment by increasing the efficacy of radiotherapy. The company develops NanoXray products to help patients receiving radiotherapy by magnifying the effect of radiotherapy within tumor cells without increasing the dose to surrounding healthy tissues. Its product candidate is NBTXR3, a preclinical research program for cancer immunotherapies.